Burning Rock Biotech (BNR) Research & Development (2019 - 2026)

Burning Rock Biotech's Research & Development history runs 8 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• In Q1 2026, Research & Development rose 28.22% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$21.8 million (up 24.1% YoY), while the FY2025 annual figure was -$23.8 million, up 25.19% from the prior year.
• Research & Development for Q1 2026 stood at -$4.0 million, up from -$5.0 million in the prior quarter.
• The five-year high for Research & Development was -$4.0 million in Q1 2026, with the low at -$18.8 million in Q1 2022.
• The 5-year median for Research & Development is -$9.1 million (2024), against an average of -$10.1 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development slumped 59.53% in 2022, then jumped 39.1% in 2025.
• Burning Rock Biotech's Research & Development stood at -$14.6 million in 2022, then increased by 29.55% to -$10.3 million in 2023, then surged by 30.56% to -$7.2 million in 2024, then surged by 30.29% to -$5.0 million in 2025, then advanced by 19.88% to -$4.0 million in 2026.
• Business Quant data shows BNR's Research & Development at -$4.0 million in Q1 2026, -$5.0 million in Q4 2025, and -$5.8 million in Q3 2025.